Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ImmunoGen to Shutter Mass. Site | Contract Pharma

What are you searching for?

Sign in
Breaking News

ImmunoGen to Shutter Mass. Site

Will rely on external manufacturing partners moving forward

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

As part of its 2017 operating results review, ImmunoGen said it is adopting a new manufacturing strategy moving forward. The company will shift to an operating model that will rely on external manufacturing and quality testing for drug substance and drug product for its development programs.

It said the implementation of this new operating model will lead to the ramp-down of manufacturing and quality activities at the company’s Norwood, MA facility by the end of 2018, with a full exit of the site by early 2019. Decommissioning the Norwood facility will result in anticipated cost savings of over $20 million during the next five years.

The Norwood facility has been a long-standing staple of ImmunoGen’s business, making drug products at the site for more than 25 years.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics